Cadila Healthcare has informed the exchanges that the US Food and Drug Administration (FDA) has inspected the drug maker’s biologics manufacturing facility (Zydus Biologics) located at the Zydus Biotech Park in Ahmedabad, from August 14 to August 24, 2018.
At the end of the inspection, no observation (483) was issued. Investors will take note of this positive development. The stock of Cadila Healthcare closed at ₹401 on the BSE, up 2.6 per cent from the previous close.